Abivax Closes $920 Million Public Offering to Fund Biotech Pipeline

Key Facts

In a move that strengthens the financial footing of the biotechnology sector, Abivax announced the formal closing of its public offering involving 7,360,000 American Depositary Shares (ADSs). According to reports, the transaction generated gross proceeds of $920 million and included the full exercise of the underwriters' option to purchase additional shares. Simultaneously, Elicio Therapeutics closed a $15 million registered direct offering to fund its cancer immunotherapy development programs.

This substantial capital raise for Abivax comes as biotech firms prioritize liquidity for advanced clinical stages, with the company intending to use the funds for chronic inflammatory disease treatments. Compared to sector peers, this offering significantly exceeds recent smaller-scale raises, such as Elicio's targeted oncology funding. Per market data, the full exercise of the over-allotment option suggests robust investor demand for the company's therapeutic pipeline despite broader market volatility.

Operationally, investors will now focus on upcoming clinical trial milestones funded by this capital injection. Looking at the economic calendar, the market awaits the U.S. JOLTs Job Openings report on June 30, 2026, which may influence risk appetite across growth sectors like biotechnology. As current price levels for ABVX are unavailable at this snapshot, the primary focus remains on the company's execution of its research strategy using the newly secured $920 million.